<DOC>
	<DOC>NCT02472795</DOC>
	<brief_summary>International trial to evaluate the biological activity and safety of ACT-334441 in lupus patients.</brief_summary>
	<brief_title>Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Male and female subjects aged 18 to 65 years with established SLE. Subjects must have active SLE, Systemic Lupus Erythematosus Disease Activity Index2000 (SLEDAI2K) score of at least 2 points for musculoskeletal or mucocutaneous manifestations and history or presence at Screening of positive antinuclear antibodies (ANA) or antidoublestranded DNA (antidsDNA) antibodies. Enrolled subjects must be treated with background SLE medications. Subjects with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and infection risks, history or presence of malignancy, history or presence of bone marrow or solid organ transplantation) or lactating or pregnant women. Subjects with severe SLE disease or with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
</DOC>